4.6 Review

Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence

Journal

WORLD JOURNAL OF GASTROENTEROLOGY
Volume 27, Issue 25, Pages 3748-3761

Publisher

BAISHIDENG PUBLISHING GROUP INC
DOI: 10.3748/wjg.v27.i25.3748

Keywords

COVID-19; SARS-CoV-2; Inflammatory bowel disease; Crohn's disease; Ulcerative colitis

Ask authors/readers for more resources

The COVID-19 outbreak since December 2019 in China has become the biggest medical issue of modern medicine, with high mortality among patients with multiple co-morbidities and overcapacity of intensive care units amplifying the impact. In the gastroenterology-related community, concern has been raised regarding patients with inflammatory bowel disease (IBD) and their susceptibility to opportunistic infections due to immunosuppressive-based therapies. The outcomes of infected patients seem to be largely dependent on the therapeutic modality they receive, with some worsening the clinical course of the infection and others mitigating its effects.
Since the initial coronavirus disease 2019 (COVID-19) outbreak in China in December 2019, the infection has now become the biggest medical issue of modern medicine. Two major contributors that amplified the impact of the disease and subsequently increased the burden on health care systems were high mortality among patients with multiple co-morbidities and overcapacity of intensive care units. Within the gastroenterology-related community, particular concern was raised with respect to patients with inflammatory bowel disease (IBD), as those patients are prone to opportunistic infections mainly owing to their immunosuppressive-based therapies. Hence, we sought to summarize current knowledge regarding COVID-19 infection in patients with IBD. Overall, it seems that IBD is not a comorbidity that poses an increased risk for COVID-19 acquisition, except in patients treated with 5-aminosalicylates. Furthermore, outcomes of the infected patients are largely dependent on therapeutic modality by which they are treated, as some worsen the clinical course of COVID-19 infection, whereas others seem to dampen the detrimental effects of COVID-19. Finally, we discussed the present and the future impact of COVID-19 pandemic and concomitantly increased health care burden on IBD-management.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available